Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept Maintenance in Rheumatoid Arthritis
NCT01578850Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jul 2012
- Primary completion
- Mar 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 19
01
Overview
Phase 4, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Etanercept + MTX with Placebo + MTX (2 arms). Primary endpoint: Percentage of Participants Who Remained in Low Disease Activity (DAS28-ESR <3.2) at 52 weeks. Started Jul 2012; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01578850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01578850.